Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Debt: 2022-2025

Historic Total Debt for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Sep 2025 value amounting to $72.3 million.

  • Tarsus Pharmaceuticals' Total Debt rose 0.80% to $72.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.3 million, marking a year-over-year increase of 0.80%. This contributed to the annual value of $71.8 million for FY2024, which is 140.94% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Total Debt of $72.3 million as of Q3 2025, which was up 0.21% from $72.1 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Total Debt ranged from a high of $72.3 million in Q3 2025 and a low of $19.2 million during Q1 2022.
  • In the last 3 years, Tarsus Pharmaceuticals' Total Debt had a median value of $71.6 million in 2024 and averaged $51.8 million.
  • Data for Tarsus Pharmaceuticals' Total Debt shows a peak YoY soared of 190.88% (in 2024) over the last 5 years.
  • Over the past 4 years, Tarsus Pharmaceuticals' Total Debt (Quarterly) stood at $19.4 million in 2022, then spiked by 53.44% to $29.8 million in 2023, then surged by 140.94% to $71.8 million in 2024, then climbed by 0.80% to $72.3 million in 2025.
  • Its Total Debt was $72.3 million in Q3 2025, compared to $72.1 million in Q2 2025 and $72.0 million in Q1 2025.